Following a full submission
AWMSG advice |
|
| Status: Recommended | |
Atazanavir (Reyataz®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients, in accordance with British HIV Association (BHIVA) guidance. Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales. |
|
Medicine details |
|
| Medicine name | atazanavir (Reyataz®) |
| Formulation | capsule |
| Reference number | 30 |
| Indication | Treatment of human immunodeficiency virus (HIV)-1 infected adults, in combination with other antiretroviral medicinal products: for treatment-naïve patients |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Infections |
| Assessment type | Full |
| Status | Recommended |
| Advice number | 2408 |
| NMG meeting date | 12/11/2008 |
| AWMSG meeting date | 10/12/2008 |
| Ratification by Welsh Government | 19/01/2009 |
| Date of issue | 21/01/2009 |